GeoVax Labs, Inc. (GOVX-OTC) Announces Publication of HIV Vaccines Review

Posted by Karen Goldfarb

October 22, 2018 at 1:47 PM

GeoVax Labs, Inc. announced today the publication of a manuscript entitled “HIV/AIDS Vaccines: 2018,” authored by Harriet L. Robinson, PhD, GeoVax’s Director of HIV Vaccines and Chief Scientific Officer Emeritus. The paper is published in the peer-reviewed journal Clinical Pharmacology & Therapeutics, a journal of the American Society for Clinical Pharmacology & Therapeutics (ASCPT), and can be viewed at Dr. Robinson provides a comprehensive review of progress toward development of an HIV/AIDS vaccine in the article, including key challenges and lessons learned from completed efficacy trials. 

Despite development of effective antiretroviral therapies (ART), only 49% and 48% of people living with HIV in the U.S. and worldwide, respectively, have drug-controlled infections. Patients without drug-controlled infections develop AIDS and spread the infection. This indicates that for eliminating HIV, there is a need for an effective vaccine to be added to the arsenal of ART. Thus, only with a demonstrated effective HIV/AIDS vaccine can people worldwide avoid the infection, ongoing health risks, and societal impact resulting from this disease. GeoVax is a leader in developing a vaccine for the clade B subtype of HIV prevalent in the Western Hemisphere, Europe, and Japan. The Company's vaccine, GOVX-B11, is currently progressing in human clinical trials with the sponsorship of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).”

GeoVax's development programs are focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please refer to our most recent Quarterly Update ( dated August 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

Download GeoVax Report 



Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.


Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

CVR Medical Corp.: Company Update (CVM-TSX; CRRVF-OTCQB)

Posted by Karen Goldfarb

October 12, 2018 at 3:35 PM

Restructuring Approved by Shareholders

CVR Medical Corp. recently announced that its Board of Directors held a Special Meeting of the Shareholders to approve, among other things, the Restructuring of the Agreement between CVR Medical Corp. and CVR Global Inc. CVR Medical Shareholders approved the restructuring as well as all other items put forth for a vote.

This restructured agreement calls for the companies to terminate and relinquish the previously agreed upon 50%/50% profit sharing structure in exchange for 30 million shares of CVR Medical Corp. stock and additional royalties associated with the commercialization and future sales of the Company's Carotid Stenotic Scan (CSS) as pictured here —a device which uses low frequency sound wave analysis to non-invasively detect and measure carotid arterial stenosis (narrowing of the blood vessels in the neck that carries blood from the heart to the brain) or occlusion (blockage)—which is the leading risk factor for stroke. As well, the current and future Intellectual Property portfolio pertaining to the CSS will now reside within CVR Medical. The agreement is subject to and will require TSX.V approval, which CVR Medical expects to be forthcoming.

With the approved transaction, CVR Global Inc. is expected to move into a milestone-driven equity-based contractor and, upon achieving the milestones stated below, could become one of the Company’s largest shareholders. These milestones include the:

  • Approval and signing of agreement (3 million shares)
  • FDA submission (2 million shares)
  • FDA clearance/approval (10 million shares)
  • Achievement of $50 million in sales from CSS Device Sales (15 million shares)—contingent on a maximum 36-month time frame from initial CSS sale

CVR Global is further expected to be granted a 7% royalty on all CSS device sales, with a 3% royalty on all associated disposable sales. With this transaction, roles are now clearly defined along with the pathway to the CSS market launch.

Announces Proposed Financing

In other recent news, CVR Medical announced that it intends to complete a non-brokered private placement financing of units for gross proceeds of up to C$2 million with a price per Unit of C$0.30 or such other price determined by CVR Medical management in compliance with TSX Venture Exchange pricing regulations.

Each Unit is to consist of one common share and one common share purchase warrant, with each Warrant exercisable to acquire one additional Share at a price of C$0.36 per Warrant Share for a period of five years following the closing date of the Financing. The Warrants will be subject to an acceleration right if on any ten consecutive trading days, beginning on the date that is four months and one day following the Closing Date, the daily closing price of the Shares on the Exchange is at or greater than C$0.50. If the Company exercises its Warrant Acceleration Right, the new expiry date of the Warrants will be the 30th day following the date on which such notice is given by the Company. The Company expects to pay finder’s fees of up to 6% in cash and 6% in finder’s warrants in connection with the Financing.

Proceeds are expected to be used for ongoing working capital requirements related to the development and commercialization of the Company’s CSS Device. Completion of the Financing is subject to Exchange acceptance and all securities issued pursuant to the Financing will be subject to a hold period of four months as required under applicable securities legislation.

Positive Interim Results Reported From Ongoing Pivotal Trial With CSS Device

The Company further announced advisory staff member Dr. Phillip J. Bendick, PhD, has released an internal report summarizing data from the pivotal clinical trials for the CSS devices in use at Thomas Jefferson University Hospital. In alignment with the previous report released by Dr. Bendick in September 2017, this preliminary report views the initial batch of data points collected within the trial as successful for the substantiation of the device’s value and efficacy.

With the trial ongoing (thus only a partial snapshot of the data), the improvements made to the CSS prior to launch of the pivotal clinical trials has generated enhanced functionality within the clinical setting. The CSS Device is being evaluated in a multi-center pivotal clinical trial to evaluate the system’s specificity and sensitivity for detecting carotid artery disease, compared to the current gold standard – duplex Doppler ultrasound. According to Dr. Bendick, “The early results of the first 144 patients enrolled in the CSS pivotal trial have shown excellent overall accuracy […] these initial results demonstrate the efficacy of the CSS as a tool to detect and guide the appropriate management of clinically important carotid artery disease in order to reduce stroke risk.”


Learn move about CVR Medical by downloading our Executive Informational Overview (EIO), a 60-page report detailing the Company's business, product development, strategic relationships, market opportunities, competition, financials, risks, and more.


Read More

Topics: cvr medical, carotid health, ischemic stroke, occlusion, duplex Doppler ultrasound (DUS), magnetic resonance angiography (MRA), computed tomography angiography (CTA), cerebral angiogram, Henry Ford Hospital, Cleveland Clinic, Canon U.S.A., transient ischemic attack (TIA), medical technology company, Carotid Stenotic Scan (CSS), stenosis, stroke, Thomas Jefferson University Hospital, ENTICES Study, CVM-TSX, CRRVF-OTCQB, atherosclerosis, Army Research Lab

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic